<?xml version="1.0" encoding="UTF-8"?>
<ref id="R46">
 <label>46.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kater</surname>
    <given-names>AP</given-names>
   </name>
   <name>
    <surname>Seymour</surname>
    <given-names>JF</given-names>
   </name>
   <name>
    <surname>Hillmen</surname>
    <given-names>P</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study</article-title>. 
  <source>
   <italic toggle="yes">J Clin Oncol.</italic>
  </source>
  <year>2019</year>;
  <volume>37</volume>:
  <fpage>269</fpage>â€“
  <lpage>277</lpage>.
  <pub-id pub-id-type="pmid">30523712</pub-id>
 </mixed-citation>
</ref>
